Torthaí cuardaigh - G. N. Hortobágyi
- 1 - 11 toradh as 11 á dtaispeáint
-
1
Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects de réir Naveen Pemmaraju, Mark F. Munsell, G. N. Hortobagyi, Sharon H. Giordano
Foilsithe / Cruthaithe 2011Revisão -
2
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review... de réir Bryan T. Hennessy, Alain Gauthier, Laura Boehnke Michaud, G. N. Hortobagyi, Vicente Valero
Foilsithe / Cruthaithe 2005Revisão -
3
Risk of Cardiac Death After Adjuvant Radiotherapy for Breast Cancer de réir Sharon H. Giordano, Yong‐Fang Kuo, J. L. Freeman, Thomas A. Buchholz, G. N. Hortobágyi, James S. Goodwin
Foilsithe / Cruthaithe 2005Revisão -
4
-
5
Survival among women with triple receptor-negative breast cancer and brain metastases de réir Shaheenah Dawood, Kristine Broglio, Francisco J. Esteva, Wei Yang, Shu‐Wan Kau, R. Islam, Constance T. Albarracin, T. Yu, M. Green, G. N. Hortobágyi, Ana M. González-Angulo
Foilsithe / Cruthaithe 2009Artigo -
6
Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications de réir Neslihan Cabıoğlu, Ayşegül A. Şahin, Paolo Morandi, F. Meric-Bernstam, R. Islam, Lin Hui, C D Bucana, Ana M. González-Angulo, G. N. Hortobágyi, Massimo Cristofanilli
Foilsithe / Cruthaithe 2009Artigo -
7
Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer de réir Neslihan Cabıoğlu, Yun Yun Gong, R. Islam, Kristine Broglio, Nour Sneige, Ayşegül A. Şahin, Ana M. González-Angulo, Paolo Morandi, C Bucana, G. N. Hortobágyi, Massimo Cristofanilli
Foilsithe / Cruthaithe 2007Artigo -
8
Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy de réir Hope S. Rugo, G. N. Hortobágyi, James C. Yao, Marianne Pavel, Alain Ravaud, David Neal Franz, François Ringeisen, Jorge D. Gallo, Nicolas Rouyrre, Oezlem Anak, Robert J. Motzer
Foilsithe / Cruthaithe 2016Revisão -
9
DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight de réir Daniel J. Weisenberger, Binh N. Trinh, Mihaela Campan, Sweta Sharma Saha, Tiffany I. Long, Suchitra Ananthnarayan, Gangning Liang, Francisco J. Esteva, G. N. Hortobagyi, F. McCormick, Peter A. Jones, Peter W. Laird
Foilsithe / Cruthaithe 2008Artigo -
10
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2 de réir Hope S. Rugo, Kathleen I. Pritchard, Michael Gnant, Shinzaburo Noguchi, Martine Piccart, G. N. Hortobagyi, José Baselga, Alejandra Perez, Matthias Geberth, Tibor Csőszi, E. Chouinard, Vichien Srimuninnimit, Puttisak Puttawibul, Janice F. Eakle, Wentao Feng, H. Bauly, Mona El-Hashimy, T Taran, Howard A. Burris
Foilsithe / Cruthaithe 2014Artigo -
11
LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor recept... de réir G. N. Hortobágyi, Salomon M. Stemmer, H.A. Burris, Yoon Sim Yap, Gabe S. Sonke, L. Hart, M. Campone, Katarína Petráková, Eric P. Winer, W Janni, Pierfranco Conté, David Cameron, Fabrice André, CL Arteaga, Juan Pablo Zarate, A. Chakravartty, Tanya Taran, Fabienne Le Gac, Patrizia Serra, Joyce O’Shaughnessy
Foilsithe / Cruthaithe 2021Artigo
Uirlisí cuardaigh:
Ábhair a bhaineann le hábhar
Internal medicine
Medicine
Oncology
Breast cancer
Cancer
Adverse effect
Confidence interval
Hazard ratio
Surgery
Chemotherapy
Clinical endpoint
Gastroenterology
Pathology
Tamoxifen
Biology
Chemokine
Chemokine receptor
Clinical trial
Disease
Environmental health
Everolimus
Gynecology
Metastatic breast cancer
Population
Proportional hazards model
Randomized controlled trial
Receptor
Retrospective cohort study
Alternative medicine
Bisulfite